The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.
A. Guerin
Employment or Leadership Position - Analysis Group
D. Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Roche
D. Latremouille-Viau
Employment or Leadership Position - Analysis Group (I)
A. P. Yu
Employment or Leadership Position - Analysis Group
E. Q. Wu
Employment or Leadership Position - Analysis Group
M. Brammer
Employment or Leadership Position - Genentech
Stock Ownership - Roche
S. A. Hurvitz
Research Funding - Genentech